Literature DB >> 427776

Glycosaminoglycans of normal and malignant cultured human mammary cells.

E V Chandrasekaran, E A Davidson.   

Abstract

Glycosaminoglycans have been characterized from a normal human breast cell line (HBL-100) and two different cell lines from human breast carcinoma (MDA-MB-231 and MCF-7). The glycosaminoglycans were labeled by exposure of cell cultures to [3H]glucosamine and [35S]sulfate and then isolated from both spent media and cells by pronase digestion and cetylpyridinium chloride fractionation. They were further characterized by (a) hexosamine composition, (b) controlled-pore glass exclusion chromatography, (c) reactivity with specific enzymes (hyaluronidase chondroitinase, heparitinase, and heparinase), (d) nitrous acid degradation, and (e) DEAD-Sephadex chromatography. The results indicate that the HBL-100 line synthesizes mainly hyaluronic acid, most of which is secreted into the medium. Chondroitin sulfate and heparan sulfate are the predominant glycosaminoglycans synthesized by the cancer lines; both are found mainly in the spent medium, but the hyaluronic acid synthesized by the MDA-MB-231 line remains cell associated. The cell-associated heparan sulfate had a molecular weight in excess of 13,000 and may contain linkages susceptible to testicular hyaluronidase. The MCF-7 cells produce significantly lower amounts of glycosaminoglycans than do the other two lines.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 427776

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Angiogenin interacts with the plasminogen activation system at the cell surface of breast cancer cells to regulate plasmin formation and cell migration.

Authors:  Sujoy Dutta; Chirosree Bandyopadhyay; Virginie Bottero; Mohanan V Veettil; Lydia Wilson; Michael R Pins; Karen E Johnson; Case Warshall; Bala Chandran
Journal:  Mol Oncol       Date:  2014-01-04       Impact factor: 6.603

2.  Growth inhibitors in plasma derived human serum.

Authors:  D A Pigott; M A Grimaldi; M L Dell'Aquila; E V Gaffney
Journal:  In Vitro       Date:  1982-07

Review 3.  Proteoglycans: pericellular and cell surface multireceptors that integrate external stimuli in the mammary gland.

Authors:  M Delehedde; M Lyon; N Sergeant; H Rahmoune; D G Fernig
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-07       Impact factor: 2.673

4.  Hyaluronidase significantly enhances the efficacy of regional vinblastine chemotherapy of malignant melanoma.

Authors:  T Spruss; G Bernhardt; H Schönenberger; W Schiess
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

5.  Hyaluronate and invasiveness of the rabbit V2 carcinoma.

Authors:  B P Toole; C Biswas; J Gross
Journal:  Proc Natl Acad Sci U S A       Date:  1979-12       Impact factor: 11.205

6.  Glycosaminoglycans in urothelial carcinomas.

Authors:  H Rübben; R Friedrichs; H W Stuhlsatz; W Lutzeyer
Journal:  Urol Res       Date:  1983

7.  Oncofetal Chondroitin Sulfate Glycosaminoglycans Are Key Players in Integrin Signaling and Tumor Cell Motility.

Authors:  Thomas Mandel Clausen; Marina Ayres Pereira; Nader Al Nakouzi; Htoo Zarni Oo; Mette Ø Agerbæk; Sherry Lee; Maj Sofie Ørum-Madsen; Anders Riis Kristensen; Amal El-Naggar; Paul M Grandgenett; Jean L Grem; Michael A Hollingsworth; Peter J Holst; Thor Theander; Poul H Sorensen; Mads Daugaard; Ali Salanti
Journal:  Mol Cancer Res       Date:  2016-09-21       Impact factor: 5.852

8.  Hyaluronidase enhances the activity of adriamycin in breast cancer models in vitro and in vivo.

Authors:  K Beckenlehner; S Bannke; T Spruss; G Bernhardt; H Schönenberg; W Schiess
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

Review 9.  Carbohydrate structure in tumor immunity.

Authors:  C L Reading; J T Hutchins
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

10.  A cell line (HBL-100) established from human breast milk.

Authors:  E V Gaffney
Journal:  Cell Tissue Res       Date:  1982       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.